PolymarketClosedCheck availabilityNo KYC2% feeVerified resolution dataFairly calibratedThis market resolved: Yes
Resolved: Jun 28, 2026, 11:21 PM
Provider-verified resolution
CoinRithm has provider-backed winner and settlement-time evidence for this market.
Winning Outcome
Yes
At 7 days out
—
At 24 hours out
—
Current implied probability
Yes 100%+0.0pt
Market quality
≤49 / 100
Low quality24h Volume
$5.6K
Liquidity
—
Liquidity unknownBid / Ask
99.9% / 100.0%
Spread
0.1 pt
Tight spread7d Change
+26.9 pts
Market data
Updated 64 days ago
StaleJun 4, 26, 7:54 PMJun 30, 26, 12:00 AM
Probability Timeline
No0%
Yes100%
100%
0%
Rules
As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viridian Therapeutics's Veligrotug as a treatment for thyroid eye disease by July 14, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
